RCS - Angle PLC - Research on HER2 assay kit showcased at AACR

AngleAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3445Ma&default-theme=true

RNS Number : 3445M  Angle PLC  15 November 2024

 For immediate release  15 November 2024

 

ANGLE plc ("the Company")

 

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT
INTERNATIONAL LIQUID BIOPSY CONFERENCE

 

Parsortix-based HER2 kit being developed to provide an optimised, easily
implemented, solution to enable product customers to undertake longitudinal,
repeat assessment of HER2 status in breast cancer

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
new data at the American Association for Cancer Research (AACR) Special
Conference in Cancer Research in San Diego, US from 13 to 16 November 2024.

 

ANGLE is presenting a poster entitled the "Development of a scoring system to
classify HER2 protein expression in Circulating Tumor Cells through
immunofluorescence following isolation using Parsortix(®) instruments" and
reports on progress of the Company's co-development programme with BioView.

 

Using the high throughput BioView Allegro Plus microscope, ANGLE and BioView
are developing an end-to-end assay kit for the evaluation of HER2 gene
amplification and protein expression in circulating tumour cells (CTCs)
harvested using the Parsortix system from the blood of metastatic breast
cancer (MBC) patients.

 

Results presented showcase the development of a scoring system for HER2
expression, which could be implemented alongside the current standard of care
which uses tumour tissue for HER2 assessment. The workflow was assessed in a
cohort of 43 MBC patients. The study identified cases where HER2 status had
changed over time and patients who were initially HER2 negative had, in the
time elapsed since tissue biopsy, become HER2 positive based on their CTC
analysis.

 

Approximately 80% of breast cancer patients are categorised as HER2 negative
based on tissue biopsy at diagnosis. However, it is well documented that HER2
status can change over time and a blood-based test could therefore enable the
identification of patients who were previously HER2 negative who may now be
HER2-low or positive and could therefore benefit from treatment with a
HER2-targeted antibody drug conjugate (ADC) or anti-HER2 therapy.

 

BioView's Chief Scientific Officer, Chassidy Johnson, commented:

"The results ANGLE will present from our co-development work at the AACR
Special Conference in Cancer Research are an important milestone in our
development programme. The results highlight the ability and robust analytical
performance of the developed HER2 CTC assay to detect ranges of HER2
expression therefore potentially identifying patients that could benefit from
anti-HER2 therapy as well as newer HER2-targeted ADCs."

 

ANGLE's Chief Scientific Officer, Karen Miller, commented:

"We are pleased to present new data from our collaborative HER2 assay
development programme at the AACR Special Conference in Cancer Research. This
study highlights the potential for longitudinal, repeat assessment of HER2 CTC
status to identify patients whose HER2 status has changed and could therefore
benefit from treatment with HER2-targeted ADC or anti-HER2 therapy."

 

The poster is available for review at: https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/) .

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFWEELELSEIF